DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZYTIGA

Summary for Tradename: ZYTIGA

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$775,269,000
drug
patent expirations by year for
 ZYTIGA

Pharmacology for Tradename: ZYTIGA

Clinical Trials for: ZYTIGA

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants
Status: Completed Condition: Healthy

A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet
Status: Completed Condition: Healthy Participants

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants
Status: Completed Condition: Healthy

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men
Status: Completed Condition: Healthy Volunteers

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Status: Active, not recruiting Condition: Prostate Cancer

A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men
Status: Completed Condition: Pharmacology

Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
Status: Not yet recruiting Condition: Prostate Cancer

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Status: Recruiting Condition: Prostate Cancer

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Status: Recruiting Condition: Prostate Cancer

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Not yet recruiting Condition: Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Biotech
ZYTIGA
abiraterone acetate
TABLET;ORAL202379Apr 28, 2011RXYes<disabled><disabled>
Janssen Biotech
ZYTIGA
abiraterone acetate
TABLET;ORAL202379Apr 28, 2011RXYes<disabled><disabled>
Janssen Biotech
ZYTIGA
abiraterone acetate
TABLET;ORAL202379Apr 28, 2011RXYes5,604,213<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc